Position: Postdoctoral Researcher
Department: Applied Functional Genomics and Translational Medical Oncology
Code number: 2019-0326
The German Cancer Research Center is the largest biomedical research institution in Germany. With approximately 3,000 employees, we operate an extensive scientific program in the field of cancer research.
The National Center of Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University Hospital and the German Cancer Aid. The NCT with sites in Heidelberg and Dresden is the leading oncological center in Germany and shall be expanded to an international center of excellence regarding point-of-care and individualised cancer medicine.
The Divisions of Applied Functional Genomics (Prof. Claudia Scholl) and Translational Medical Oncology (Prof. Stefan Fröhling) at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg have two postdoctoral openings.
1) Our ambition is to improve the way we practice oncology towards a more rational and personalized approach. We engage in all aspects of the translational research process, inlcuding one of the most comprehensive cancer molecular diagnostics programs worldwide (NCT/DKTK MASTER), in which we have analyzed more than 1,600 tumor samples by whole-exome or genome and RNA sequencing and discovered previously unrecognized recurrent genetic alterations in various tumor types. In addition, by using large-scale functional approaches, such as CRISPR/Cas9 screening, we discover specific gene and network essentialities in the context of different cancer types, gene mutations, and drug exposures. The postdoctoral researcher has the opportunity to explore genomics-based discoveries in the laboratory and study the functional and mechanistic consequences of genes on small and large scale.
2) Chordomas are devastating and difficult-to-treat bone tumors whose pathophysiology is poorly understood. An established driver of chordomagenesis and attractive drug target is the embryonic transcription factor brachyury. The postdoctoral researcher will develop designed ankyrin repeat proteins (DARPins) for binding and inhibiting brachyury, and use these DARPins to analyze the function of brachyury in chordoma and to develop molecularly targeted therapies.
- We are looking for a brilliant early-career scientist who is highly motivated, ambitious, hard-working, and able to pursue research projects independently.
- Applicants must hold a Ph.D. in biology, biochemistry, biotechnology, or a related field, and have a track record in international peer-reviewed journals.
- Expertise in molecular and cellular biology, with specific focus on genome engineering techniques is advantageous.
- Profound knowledge of cancer biology, excellent communication skills, and proficiency in English are mandatory.
Applications should include a CV, motivation letter, expected availability date, copies of relevant certificates, a complete list of publications, and three references to your application.
- Interesting, versatile workplace
- International, attractive working environment
- Campus with modern state-of-the-art infrastructure
- Salary according to TV-L including social benefits
- Possibility to work part-time
- Flexible working hours
- Comprehensive further training program
- Access to the DKFZ International Postdoc Program
Earliest possible start date: as soon as possible
Duration: The position is limited to 2 years with the possibility of prolongation.
The position can in principle be part-time.
Application deadline: 31.10.2019
Phone +49 (0)6221/42-1633
Please note that we do not accept applications submitted via email.